<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107475">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01762163</url>
  </required_header>
  <id_info>
    <org_study_id>QZTL2013</org_study_id>
    <secondary_id>QZTL</secondary_id>
    <nct_id>NCT01762163</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke</brief_title>
  <official_title>Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke With Qi Deficiency and Blood Stasis Syndrome: a Multicenter, Randomized,Double-blind，Placebo- and Active-controlled Adaptive Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China  Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China  Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 20-week study consisting of a 12-week  multicenter, randomized,double-blind
      adaptive study to compare efficacy and safety of Qizhitongluo Capsule,Naoxintong Capsule and
      placebo in the recovery phase of ischemic stroke with qi deficiency and blood stasis
      syndrome, and a 8-week post-treatment safety follow-up.After 312 patients complete 12 weeks
      of treatment there will be an interim analysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change in the Lower Extremity Fugl-Meyer score</measure>
    <time_frame>baseline, after 4,12 weeks of treatment, after  90 days of onset.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Aphasia Quotient（AQ) score</measure>
    <time_frame>baseline, after 4,12 weeks of treatment, after  90 days of onset.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Barthel Index score and proportion of subjects with Barthel Index score ≥90</measure>
    <time_frame>baseline, after 4,12 weeks of treatment, after  90 days of onset.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Upper Extremity Fugl-Meyer score</measure>
    <time_frame>baseline, after 4,12 weeks of treatment, after  90 days of onset.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the total Fugl-Meyer motor score</measure>
    <time_frame>baseline, after 4,12 weeks of treatment, after  90 days of onset.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the syndrome score of Qi Deficiency and Blood Stasis</measure>
    <time_frame>baseline, after 4,12 weeks of treatment, after  90 days of onset.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incidence of New-onset cardiovascular events</measure>
    <time_frame>during the 20-weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma glucose and lipid concentrations and blood coagulate</measure>
    <time_frame>baseline and after 12 weeks of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical examination、 laboratory tests and ECG</measure>
    <time_frame>baseline and  after 12 weeks of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incidence of adverse events</measure>
    <time_frame>during the 20-weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>during the 20-weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>The modified Rankin Scale(mRS) score</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>the National Health Interview Surveys (NHISS) score</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">624</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Qizhitongluo Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night;the routine recovery training.
intervention treatment:the Capsules were administered orally, four capsules each time, three times a day after each meal（placebo was taken only after lunch, and Qizhitongluo Capsule was taken after breakfast and supper)for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naoxintong Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night; the routine recovery training.
intervention treatment:Naoxintong Capsule was administered orally, four capsules each time, three times a day after each meal for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night and the routine recovery training.
intervention treatment:placebo capsule was administered orally  four capsules each time, three times a day after each meal for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qizhitongluo Capsule</intervention_name>
    <arm_group_label>Qizhitongluo Capsule</arm_group_label>
    <other_name>QZTL group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naoxintong Capsule</intervention_name>
    <arm_group_label>Naoxintong Capsule</arm_group_label>
    <other_name>NXT group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin Enteric-coated Tablets</intervention_name>
    <arm_group_label>Qizhitongluo Capsule</arm_group_label>
    <arm_group_label>Naoxintong Capsule</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>the routine recovery training</intervention_name>
    <arm_group_label>Qizhitongluo Capsule</arm_group_label>
    <arm_group_label>Naoxintong Capsule</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Qizhitongluo Capsule</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age≥35 years and &lt;80 years;

          -  Diagnosis of ischemic stroke in recovery phase, according to the Chinese guidelines
             for the diagnosis and treatment of acute ischemic stroke 2010;

          -  Diagnosis of ischemic stroke with qi deficiency and blood stasis syndrome;

          -  The interval from the onset to recruitment was 15-28 days;

          -  FM score &lt;90 or AQ＜93.8 and diagnosis of  aphasia;

          -  Diagnosis of cerebral anterior circulation obstruction;

          -  4≤ NIHSS score＜20;

          -  Patient is willing to participate voluntarily and to sign a written patient informed
             consent.

        Exclusion Criteria:

          -  Evidence of intracranial hemorrhage (ICH) or other cerebral diseases (eg.vascular
             malformation, tumor, abscess or multiple sclerosis etc.) on  CT or MRI.

          -  Known history of allergy or suspected allergic to the study drugs.

          -  Liver function impairment with the value of ALT or AST over 1.5-fold of normal value.

          -  Renal dysfunction with the value of serum creatinine over 1.5-fold of normal value.

          -  Cerebral embolism caused by cerebral tumor, cerebral trauma, cerebral parasitosis,
             rheumatic heart disease, coronary heart disease or other cardiac diseases complicated
             with atrial fibrillation.

          -  Prestroke score on the mRS ≥2.

          -  Space-occupying lesions, CT or MRI revealed midline structure shift; CT revealed that
             massive cerebral infarction including more than one lobe of brain or over 1/3 of
             blood-supply area of middle cerebral artery.

          -  Disable patients prescribed by law（blind, deaf, dumb, mental retardation, mental
             disorders and physical disabilities which due to other causes affect neural function
             deficient scale).

          -  Hemorrhagic tendency or recent severe or dangerous bleeding in 3 months.

          -  Suspected addicted into alcohol or drug abuse; with severe complications that would
             make the condition more complicated assessed by the investigator.

          -  Woman with pregnancy, lactation or positive result of pregnancy test, or women who
             want to be pregnant in recent.

          -  Patient who is participating in other trials or has been participated in other trials
             in recent 3 months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhong Wang, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yingzhen Xie, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dongzhimen Hospital, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhong Wang, Ph.D</last_name>
    <phone>+86-10-64014411</phone>
    <phone_ext>3308</phone_ext>
    <email>zhonw@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongli Wu, M.D.</last_name>
    <phone>+86-10-64014411</phone>
    <phone_ext>2802</phone_ext>
    <email>holiwu@yeah.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi University of Chinese Medicine</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liwu Huang</last_name>
      <phone>15878806668</phone>
      <email>liwuhuang5912@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Wei Chen</last_name>
      <phone>13978824543</phone>
      <email>chenwei8126@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Langfang TCM Hospital</name>
      <address>
        <city>Langfang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dequan Liu, Professor</last_name>
      <phone>15831686788</phone>
      <email>lfliudequan@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jingjing Chang</last_name>
      <phone>18031603677</phone>
      <email>33804261@qq.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>the First affiliated Hospital of Henan University of TCM</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinzhi Wang, Professor</last_name>
      <phone>+86-371-66220364</phone>
      <email>znqznq@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanmei Li</last_name>
      <phone>13764564457</phone>
      <email>liyanmei22@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>the affiliated Hospital to Changchun University of Chinese Medicine</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianjun Zhao, associate professor</last_name>
      <phone>+86-15948000771</phone>
      <email>Zhaojianjun8777@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yue Wang</last_name>
      <phone>15844009550</phone>
      <email>2573999012@qq.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Dalian University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing He</last_name>
      <phone>15524587532</phone>
    </contact>
    <contact_backup>
      <last_name>Xinyi Gu</last_name>
      <phone>13478650197</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>201 Hospital of People's Liberation Army</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Liu</last_name>
      <phone>18900992700</phone>
      <email>liuh2002@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Xia Li</last_name>
      <email>41768979@qq.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Second Hospital affiliated to Liaoning University of Traditional Chinese Medicine</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuying Jiao, Professor</last_name>
      <phone>024-86508813</phone>
      <email>inzyjiaofuying@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Liang Yao</last_name>
      <phone>15002461511</phone>
      <email>yaoliang83730@sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>West China Hospital,Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Qu, associate professor</last_name>
      <phone>+86-28-85423523</phone>
      <email>quyben@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi Li</last_name>
      <phone>13558660273</phone>
      <email>58317801@qq.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Guang'anmen Hospital Nan District,China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wentao Ding, associate professor</last_name>
      <phone>+86-13261853981</phone>
      <email>DWTHRC@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Bo Zhang</last_name>
      <phone>18612180053</phone>
      <email>zhangbo886@sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine</name>
      <address>
        <city>Beijing</city>
        <zip>100700</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingzhen Xie, Professor</last_name>
      <phone>+86-10-84013182</phone>
    </contact>
    <contact_backup>
      <last_name>Yizhan Wang</last_name>
      <phone>18810466346</phone>
      <email>724277231@qq.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>First Teaching Hospital of Tianjin University of TCM</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhihong Meng, Professor</last_name>
      <phone>+86-18722699933</phone>
      <email>jy1988mzh@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaoyu Dai</last_name>
      <phone>13012289781</phone>
      <email>huangdxy@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>January 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China  Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zhong Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Ischemic Stroke,adaptive design, randomized, double-blind</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
